drug delivery technology News
-
LayerBio Awarded $1.2 Million from NIH to Develop Sustained-Release Glaucoma Drug
Founded in 2013 as a spin-off from the lab of Dr. Paula Hammond at MIT, LayerBio is developing novel drug delivery products for ophthalmology, wound care, tendon repair and other unmet medical needs. The National Eye Institute at the National Institutes of Health awarded LayerBio a $1.2 million small business grant to develop its sustained-release formulation of the glaucoma drug travoprost. ...
-
Aerogen leading the way for inhaled COVID-19 vaccine delivery
Company’s aerosol drug delivery technology used in Phase 1 clinical trial to deliver inhaled type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults without COVID-19 from China The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology1 that mitigates the transmission of patient-generated infectious aerosol during ventilation2–7. Hospitals around the ...
By Aerogen
-
Cingulate Benzinga All Live Access Appearance Rescheduled for December 16
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on Friday December 16, 2022, at 9:20 a.m. ...
By Cingulate
-
Cingulate to Participate in Benzinga All Live Access Event
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Friday December 2, 2022, at 10 a.m. CST. The ...
By Cingulate
-
CD Formulation Shows the Ability of Coated Microneedle Preparation Technology for Novel Drug Delivery
Advancements in drug delivery technology have paved the way for more efficient and targeted treatment options. Among these innovations is the development of coated microneedle preparation technology, which has shown promising results in delivering novel drugs to patients. CD formulation involves coated microneedles with specific drug compounds, allowing for controlled and sustained drug delivery. ...
-
Christer Nordstedt resigns as acting CEO of Vivesto
The process of recruiting a permanent CEO has been accelerated. Christer Nordstedt will continue in his current role until 30 November 2022 and will thereafter remain as senior advisor to Vivesto on a consultancy basis. Christer Nordstedt has been acting CEO since 21 July 2022. Peter Zonabend, Chairman of the Board of Vivesto, said: “We would like to thank Christer for his efforts during ...
By Vivesto AB
-
EsoCap announces issue of U.S. patent for its smart application technology in the upper gastrointestinal tract
EsoCap AG has announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,744,095 on August 18, 2020. The patent is directed at the smart application technology enabling specific sitedirected treatment of several diseases of the esophagus. “Issue of the U.S. patent is a major milestone confirming the novelty of EsoCap’s proprietary ...
By EsoCap AG
-
Vivesto winds down its activities in Russia
This means that the distribution activities for Paclical (Apealea) in Russia and the Commonwealth of Independent States (CIS) will be paused until further notice. The wind down of Vivesto’s activities in Russia means that a write down of SEK 44.6 million will be carried out, equal to the net book value of the capitalized development costs for Paclical after amortization as of June 30, ...
By Vivesto AB
-
PolyActiva to Present Positive Clinical Trial Results at the 2022 American Glaucoma Society Annual Meeting
Melbourne, Australia – March 4, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that data from the Phase IIa study of its PA5108 Ocular Implant for the treatment of Primary Open-Angle ...
-
CD Formulation Expands Its Service Portfolio for Drug Delivery Research
As a reliable service provider in pharmaceutical formulation development, CD Formulation constantly expands its service range and today announces to offer a comprehensive portfolio of services for drug delivery system (DDS) research, including microneedle technology services, oral thin films technology services, microencapsulation technology services, liposome drug delivery technology services, ...
-
Camurus’ Nomination Committee appointed for the Annual General Meeting 2022
Camurus today announced that the Nomination Committee for the Annual General Meeting, AGM, 2022 consists of the following persons, who together represent about 49 percent of the total number of shares and votes in Camurus based on the last known shareholder information: Per Sandberg, appointed by Sandberg Development AB, Max Mitteregger, appointed by Gladiator, Arne Lööw, appointed ...
By Camurus AB
-
Aerogen and CanSinoBIO agree on landmark development and commercial supply partnership for world’s first inhaled Covid-19 vaccine delivery
Following months of collaborative development work, Aerogen® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology. The ...
By Aerogen
-
Nomination Committee appointed for the 2023 Annual General Meeting in Vivesto
In accordance with the principles for appointing a Nomination Committee, which were adopted at Vivesto AB’s (”Vivesto”) Annual General Meeting on 25 May 2022, it is hereby announced that the Nomination Committee for the 2023 Annual General Meeting has been appointed, based on the ownership structure as per 30 September 2022. The Nomination Committee for the 2023 Annual ...
By Vivesto AB
-
Announcement: Numedico and Omikron Group
Numedico Technologies Pty Ltd (Numedico) and Omikron Group Ltd (OGL) are pleased to announce the completion and settlement of the acquisition of the global ClickZip assets and Omikron business. Signed in May 2020, the acquistion brings the assets and international business of the ClickZip® Needle Retractable Safety Syringe into Numedico’s expanding portfolio of safe medical devices and ...
-
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem Cell Drug Delivery Technology
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has expanded its existing collaboration with Advanced BioMatrix, a division of BICO Group AB (STO: BICO), for Lineage’s HyStem cell/drug delivery technology. Under the expanded collaboration, Advanced ...
-
CD Formulation Introduces Microneedle Patch Innovations for Enhanced Drug Delivery Efficiency
CD Formulation, a leading innovator in drug delivery technologies, has recently introduced a series of groundbreaking microneedle patch innovations that promise to revolutionize the way drugs are administered. Microneedle patches are a novel drug delivery system that utilizes tiny needles to painlessly penetrate the skin's outer layer and deliver medication directly into the bloodstream. This ...
-
Vivesto announces that Christer Nordstedt will remain as acting CEO during a transition period
On November 21, 2022, Vivesto announced that Erik Kinnman was appointed as the new CEO of Vivesto, effective no later than May 20, 2023. Vivesto has today agreed with Christer Nordstedt that he will remain in his current position as acting CEO of Vivesto on a part-time basis until Erik Kinnman takes office. "We are very pleased that Christer can remain in his role as acting CEO of Vivesto. ...
By Vivesto AB
-
Dr. Ryan Gordon joins the Stem Pharm team as Sr. V.P. of Business Development
Dr. Ryan Gordon has joined the Stem Pharm team as Sr. V.P. of Business Development and Commercialization. Gordon brings to Stem Pharm over 20 years of business, R&D, and operational experience in developing and commercializing innovative biopharmaceutical technologies to revolutionize disease treatment and improve patient outcomes. He has been a valued leader at large companies (3M) and ...
-
Vivesto and CEO Francois Martelet have agreed on ending the employment relationship
Vivesto AB (“Vivesto” or the “Company”), an oncology-focused specialty pharmaceutical company, hereby announces that the Board of Directors of the Company has today agreed with the Company’s CEO, Francois Martelet, to mutually terminate his employment. Pursuant to the agreement, Francois’ employment will end on 21 July 2022. Vivesto has commenced the ...
By Vivesto AB
-
Combines mesenchymal stem-cell-based product, with Kurve’s intranasal drug delivery technology
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic virus bearing product. The results ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you